TNFRSF8 and primary cutaneous T-cell non-Hodgkin lymphoma: In an attempt to achieve sustainable responses with manageable side effects, many ongoing clinical trials have been registered to evaluate CD30 CAR-T efficacy in treating Hodgkin and non-Hodgkin lymphoma (NCT02917083, NCT01316146, NCT03049449, NCT02690545), but none are studying CTCL treatment-specific diseases.